You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

APL

Showing 1 - 25 of 331
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Bladder Cancer Trial in Melbourne (APL-1202 and APL-1501 (Single ascending dose), APL-1202 and APL-1501 (Multiple Ascending

Not yet recruiting
  • Bladder Cancer
  • APL-1202 and APL-1501 (Single ascending dose)
  • APL-1202 and APL-1501 (Multiple Ascending dose)
  • Melbourne, Victoria, Australia
    Nucleus Network Pty Ltd
Sep 11, 2023

Ulcerative Colitis Trial in Whittier (APL-1401, Placebo)

Not yet recruiting
  • Ulcerative Colitis
  • Whittier, California
    New Hope Research Development
Feb 15, 2023

APL Trial in Shanghai (Chidamide+venetoclax)

Active, not recruiting
  • APL
  • Shanghai, Shanghai, China
    Jiong HU
May 30, 2023

Newly-diagnosed APL (de Novo or Therapy-related), Relapsed APL Trial in Dresden (observational)

Recruiting
  • Newly-diagnosed APL (de Novo or Therapy-related)
  • Relapsed APL
  • observational
  • Dresden, Germany
    Prof. Dr. U. Platzbecker
Aug 10, 2022

Fallopian Tube Carcinosarcoma, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma Trial in Buffalo

Not yet recruiting
  • Fallopian Tube Carcinosarcoma
  • +10 more
  • Bevacizumab
  • +4 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Dec 29, 2022

Bioequivalence Trial in Auckland (APL-101, PLB-1001)

Recruiting
  • Bioequivalence
  • Auckland, New Zealand
    New Zealand Clinical Research
Jun 13, 2022

The Acute Promyelocytic Leukaemia Asian Consortium Project

Recruiting
  • Acute Promyelocytic Leukemia
    • Hong Kong, Hong Kong
      Department of Medicine, the University of Hong Kong, Queen Mary
    Oct 3, 2022

    Hepatocellular Carcinoma, Renal Cell Carcinoma Trial in Australia, New Zealand (APL-501, APL-101, Nivolumab)

    Terminated
    • Hepatocellular Carcinoma
    • Renal Cell Carcinoma
    • APL-501
    • +2 more
    • Albury, New South Wales, Australia
    • +8 more
    May 3, 2022

    APL Tendons in Thumb CMC Joint and Osteoarthritis

    Not yet recruiting
    • Thumb Osteoarthritis
    • Anatomical dissection and Immunohistochemical techniques
    • Barcelona, Spain
    • +1 more
    Nov 23, 2022

    Acute Promyelocytic Leukemia, Induction Therapy, Oral Trial in Beijing (Etoposide, Daunorubicin)

    Recruiting
    • Acute Promyelocytic Leukemia
    • +2 more
    • Beijing, Beijing, China
      Peking University Institute of Hematology
    Apr 26, 2023

    Solid Tumor, Microsatellite Instability, Mismatch Repair Deficiency Trial in Australia (APL-501)

    Completed
    • Solid Tumor
    • +3 more
    • Camperdown, New South Wales, Australia
    • +4 more
    May 5, 2022

    Non-muscle Invasive Bladder Cancer Trial in Shanghai (APL-1202 in combination with Epirubicin, Placebo in combination with

    Active, not recruiting
    • Non-muscle Invasive Bladder Cancer
    • APL-1202 in combination with Epirubicin
    • Placebo in combination with Epirubicin
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Feb 21, 2022

    Non-muscle Invasive Bladder Cancer Trial in Shanghai (APL-1202, Epirubicin Hydrochloride)

    Recruiting
    • Non-muscle Invasive Bladder Cancer
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Feb 21, 2022

    Muscle Invasive Bladder Cancer Trial in New York, Shanghai (APL-1202 in combination with tislelizumab, Tislelizumab alone)

    Recruiting
    • Muscle Invasive Bladder Cancer
    • APL-1202 in combination with tislelizumab
    • Tislelizumab alone
    • New York, New York
    • +1 more
    Feb 21, 2022

    Bladder Cancer Trial in Randwick (APL-1202+APL-1501 ER Tablets 3+APL-1501 ER Tablets 2, APL-1501 ER Tablets 3+APL-1202+APL-1501

    Completed
    • Bladder Cancer
    • APL-1202+APL-1501 ER Tablets 3+APL-1501 ER Tablets 2
    • APL-1501 ER Tablets 3+APL-1202+APL-1501 ER Tablets 2
    • Randwick, New South Wales, Australia
      Scientia clinical research
    Jun 25, 2021

    Advanced Solid Tumor Trial in Beijing (APL-102 Capsules)

    Recruiting
    • Advanced Solid Tumor
    • APL-102 Capsules
    • Beijing, China
      Cancer Institute and Hospital, Chinese Academy of Medical Scienc
    Sep 14, 2021

    Geographic Atrophy Trial in United States (PEGCETACOPLAN (APL-2))

    Completed
    • Geographic Atrophy
    • PEGCETACOPLAN (APL-2)
    • Bakersfield, California
    • +4 more
    Nov 8, 2021

    Drug Interaction Trial in Uppsala (Drug Drug Interaction)

    Recruiting
    • Drug Interaction
    • Drug Drug Interaction
    • Uppsala, Sweden
      CTC Clinical Trial Consultants AB
    Apr 13, 2023

    Promyelocytic Leukemia Trial in Monterrey (Arsenic trioxide, all-trans retinoic acid)

    Recruiting
    • Promyelocytic Leukemia
    • Arsenic trioxide
    • all-trans retinoic acid
    • Monterrey, Nuevo Leon, Mexico
      Hopsital Universitario Dr. Jose E. Gonzalez, Centro Universitari
    Aug 9, 2022

    Antiphospholipid Antibodies on Thrombin Generation During

    Not yet recruiting
    • Antiphospholipid Syndrome
    • COVID-19
    • characterization of aPL
    • Nancy, France
      Virginie Dufrost
    Nov 18, 2021

    APL Trial in Valencia (Atra, Idarubicin, methotrexate)

    Recruiting
    • APL
    • Valencia, Spain
      Hospital La Fe
    Mar 22, 2021

    C3G, IC-MPGN, C3 Glomerulopathy Trial (Pegcetacoplan)

    Not yet recruiting
    • C3G
    • +11 more
    • (no location specified)
    Apr 13, 2023

    COVID, Covid-19, Coronavirus Trial in Brazil, United States (APL-9, Vehicle Control)

    Completed
    Has Results
    • COVID
    • +8 more
    • Fresno, California
    • +23 more
    Mar 21, 2022

    RWE of 1st Line Treatment With ATO/ATRA for Adult APL

    Recruiting
    • Promyelocytic Leukemia, Adult Acute
    • Evaluation of first line treatment with ATO/ATRA outcome
    • Caba, Argentina
    • +1 more
    Nov 9, 2021

    Antiphospholipid Syndrome Trial in New York (Hydroxychloroquine)

    Terminated
    Has Results
    • Antiphospholipid Syndrome
    • New York, New York
      Hospital for Special Surgery
    Aug 18, 2021